OPNT - Opiant says pharmacodynamic study shows benefit of its opioid overdose treatment OPNT003

Opiant Pharmaceuticals (NASDAQ:OPNT) on Wednesday announced what it deemed to be positive results from a pharmacodynamic study of its investigational opioid overdose treatment OPNT003, nasal nalmefene. OPNT stock rockets 21.2% to $23.99 in aftermarket trade. Pharmacodynamics is the study of a drug's molecular, biochemical and physiological effects or actions. OPNT said the study compared 3 mg OPNT003 with 4 mg standard nasal naloxone hydrochloride in reversing the respiratory depression produced by synthetic opioid remifentanil. A preliminary analysis on the 50 healthy volunteers that completed the study found that OPNT003 produced, at the primary end point of five minutes, a greater reversal in remifentanil-induced respiratory depression that was nearly twice that produced by nasal naloxone. OPNT said the completion of the pharmacodynamic study concludes the planned clinical development program for OPNT003. The company expects to complete a new drug application filing for OPNT003 in H2 2022.

For further details see:

Opiant says pharmacodynamic study shows benefit of its opioid overdose treatment OPNT003